1
|
Azri C, Dusser P, Eid L, Barreau E, Kone-Paut I, Borocco C, Galeotti C, Saad S, Labetoulle M, Rousseau A. Ocular involvement in pediatric Behçet's disease: is it different than in adults? (a short case series and mini review). BMC Ophthalmol 2023; 23:474. [PMID: 37990307 PMCID: PMC10664259 DOI: 10.1186/s12886-023-03197-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2022] [Accepted: 11/01/2023] [Indexed: 11/23/2023] Open
Abstract
BACKGROUND Pediatric Behçet's disease (PBD) is rarer than BD and can be a challenging diagnosis as clinical picture may be incomplete. As in adult patients, sight-threatening ocular manifestations may lead to diagnosis. In this study, we aimed to report a series of cases of PBD with ocular manifestations and provide a review of the literature. METHODS Retrospective case series of PBD patients with ocular manifestations. Demographic, ophthalmological and systemic data at presentation and during follow-up were collected and analyzed. RESULTS Four patients, aged 13.0 ± 2.9 years (9-16) were included. Posterior uveitis with retinal vasculitis, papillitis and macular edema was present in all patients, with associated anterior uveitis in 2 cases. Other features included occlusive vasculitis (2/4) and necrotizing retinitis (2/4). All patients were improved by systemic treatments except one patient with severe bilateral optic neuropathy. Ocular manifestations were the presenting symptoms in 3/4 cases. CONCLUSION Ocular manifestations and systemic associations of PBD are comparable to those encountered in adult patients. The lack of complains in pediatric patients may lead to a longer diagnosis delay, especially in unilateral uveitis. Aggressive and long-term treatment is mandatory to prevent vision loss and recurrences.
Collapse
Affiliation(s)
- Casem Azri
- Service d'Ophtalmologie, Assistance Publique Hôpitaux de Paris (AP-HP), Université Paris-Saclay. Centre de Référence Pour Les Maladies Rares en Ophtalmologie (OPHTARA), Hôpital Bicêtre, 78, Rue du Général Leclerc, 94275, Le Kremlin Bicêtre, France
| | - Perrine Dusser
- Paediatric Rheumatology Department, APHP, Bicêtre Hospital, Le Kremlin-Bicêtre, 94270, France
- Centre de Référence Des Maladies Auto-Inflammatoires Et Des Amyloses Inflammatoire (CEREMAIA), Le Kremlin-Bicêtre, France
| | - Laura Eid
- Service d'Ophtalmologie, Assistance Publique Hôpitaux de Paris (AP-HP), Université Paris-Saclay. Centre de Référence Pour Les Maladies Rares en Ophtalmologie (OPHTARA), Hôpital Bicêtre, 78, Rue du Général Leclerc, 94275, Le Kremlin Bicêtre, France
| | - Emmanuel Barreau
- Service d'Ophtalmologie, Assistance Publique Hôpitaux de Paris (AP-HP), Université Paris-Saclay. Centre de Référence Pour Les Maladies Rares en Ophtalmologie (OPHTARA), Hôpital Bicêtre, 78, Rue du Général Leclerc, 94275, Le Kremlin Bicêtre, France
| | - Isabelle Kone-Paut
- Paediatric Rheumatology Department, APHP, Bicêtre Hospital, Le Kremlin-Bicêtre, 94270, France
- Centre de Référence Des Maladies Auto-Inflammatoires Et Des Amyloses Inflammatoire (CEREMAIA), Le Kremlin-Bicêtre, France
| | - Charlotte Borocco
- Paediatric Rheumatology Department, APHP, Bicêtre Hospital, Le Kremlin-Bicêtre, 94270, France
- Centre de Référence Des Maladies Auto-Inflammatoires Et Des Amyloses Inflammatoire (CEREMAIA), Le Kremlin-Bicêtre, France
| | - Caroline Galeotti
- Paediatric Rheumatology Department, APHP, Bicêtre Hospital, Le Kremlin-Bicêtre, 94270, France
- Centre de Référence Des Maladies Auto-Inflammatoires Et Des Amyloses Inflammatoire (CEREMAIA), Le Kremlin-Bicêtre, France
| | - Sami Saad
- Service d'Ophtalmologie, Centre Hospitalier National Ophtalmologique des 15-20, Paris, France
| | - Marc Labetoulle
- Service d'Ophtalmologie, Assistance Publique Hôpitaux de Paris (AP-HP), Université Paris-Saclay. Centre de Référence Pour Les Maladies Rares en Ophtalmologie (OPHTARA), Hôpital Bicêtre, 78, Rue du Général Leclerc, 94275, Le Kremlin Bicêtre, France
| | - Antoine Rousseau
- Service d'Ophtalmologie, Assistance Publique Hôpitaux de Paris (AP-HP), Université Paris-Saclay. Centre de Référence Pour Les Maladies Rares en Ophtalmologie (OPHTARA), Hôpital Bicêtre, 78, Rue du Général Leclerc, 94275, Le Kremlin Bicêtre, France.
- Department of Immunology of Viral, Auto-Immune Disease, Hematological and Bacterial Diseases (IMVA-HB), UMR1184, CEA, Fontenay-Aux-Roses, France.
| |
Collapse
|
2
|
Francois J, Moulinet T, Neiter E, Ehrardt A, Conart JB, Angioi-Duprez K. [Behçet's disease : Description and analysis of a French single-center retrospective study of 51 patients]. J Fr Ophtalmol 2021; 44:711-717. [PMID: 33741217 DOI: 10.1016/j.jfo.2020.04.064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2019] [Revised: 04/23/2020] [Accepted: 04/24/2020] [Indexed: 11/16/2022]
Abstract
PURPOSE To evaluate if the presence of uveitis in Behçet's disease (BD) is associated with a particular clinical phenotype and to analyze the prognostic impact of a missed diagnosis of BD at the time the uveitis is diagnosed. MATERIEL AND METHODS Ophthalmologic and systemic clinical features of 51 patients with BD were recorded retrospectively. We compared the clinical phenotype of patients with ocular manifestations with those without ocular manifestations. The patients were divided into two groups depending on the progression of their visual acuity: "decreased visual acuity" versus "stable or improved visual acuity." RESULTS In the group of patients with ocular involvement, there was a mean 2.3 systemic manifestations, vs. 3.2 in the group without ocular manifestations (P=0.004). When BD was diagnosed prior to the onset of uveitis, we counted fewer patients in the "decreased visual acuity" group in comparison with the patients who had no prior diagnosis of BD at the onset of the uveitis (91.3% in the "decreased visual acuity" group, P=0.04). The time before initiation of immunosuppressive treatment or a biological agent was shorter for these patients (4.4 vs. 39.3 months, P=0.007). CONCLUSION It appears that different phenotypes exist according to whether or not the BD patient has ocular involvement. Moreover, the visual prognosis is better if the uveitis occurs in patients who have already been diagnosed with BD, due to earlier initiation of immunosuppressive therapy.
Collapse
Affiliation(s)
- Julie Francois
- Département d'ophtalmologie, Centre Hospitalier Universitaire de Nancy, Vandœuvre-lès-Nancy, France.
| | - Thomas Moulinet
- Département de médecine interne, Centre Hospitalier Universitaire de Nancy, Vandœuvre-lès-Nancy, France
| | - Estelle Neiter
- Département d'ophtalmologie, Centre Hospitalier Universitaire de Nancy, Vandœuvre-lès-Nancy, France
| | - Alix Ehrardt
- Département d'ophtalmologie, Centre Hospitalier Universitaire de Nancy, Vandœuvre-lès-Nancy, France
| | - Jean-Baptiste Conart
- Département d'ophtalmologie, Centre Hospitalier Universitaire de Nancy, Vandœuvre-lès-Nancy, France
| | - Karine Angioi-Duprez
- Département d'ophtalmologie, Centre Hospitalier Universitaire de Nancy, Vandœuvre-lès-Nancy, France
| |
Collapse
|